ConductScience.org, home

Paper17547834

NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes.

Bugianesi E and 2 others. Curr Diab Rep, 2007. Cited by 42 papers, by iCite.

Cite this record

ConductScience Library. NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes. Papers, record 17547834. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/17547834

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
NASH and the risk of cirrhosis and hepatocellular carcinoma in type 2 diabetes.
PubMed
Journal
Curr Diab Rep
PubMed
Year
2007
PubMed
Publication types
Journal Article, Review
PubMed
Citations, by iCite
42
iCite
Relative citation ratio, by iCite
0.96
iCite
Revised in PubMed
2026-10-11
PubMed

Authors3

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Bugianesi EElisabetta
2Vanni EEster
3Marchesini GGiulio

Source PubMed

Download CSV of authors

Topics10

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Carcinoma, HepatocellularMajor topic
Diabetes Mellitus, Type 2Major topic
Fatty LiverMajor topic
Liver DiseasesMajor topic
Cohort Studies
Female
Humans
Liver Cirrhosis
Male
Prevalence

Source PubMed

Download CSV of topics

References51

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
19918906Association of diabetes mellitus and chronic hepatitis C virus infection.Hepatology1999https://conductscience.org/library/papers/9918906PubMed
211003611Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study.Hepatology2000https://conductscience.org/library/papers/11003611PubMed
312055590Diabetes increases the risk of acute hepatic failure.Gastroenterology2002https://conductscience.org/library/papers/12055590PubMed
412016429Nonalcoholic fatty liver disease.Gastroenterology2002https://conductscience.org/library/papers/12016429PubMed
516108839Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults.Diabet Med2005https://conductscience.org/library/papers/16108839PubMed
62819932Diabetes mellitus and primary hepatocellular carcinoma.Q J Med1986https://conductscience.org/library/papers/2819932PubMed
715753540Diabetes increases the risk of hepatocellular carcinoma in the United States: a population based case control study.Gut2005https://conductscience.org/library/papers/15753540PubMed
815242486Non-alcoholic steatohepatitis in type 2 diabetes mellitus.J Gastroenterol Hepatol2004https://conductscience.org/library/papers/15242486PubMed
91660542Nonviral risk factors for hepatocellular carcinoma in a low-risk population, the non-Asians of Los Angeles County, California.J Natl Cancer Inst1991https://conductscience.org/library/papers/1660542PubMed
1015030972The spectrum expanded: cryptogenic cirrhosis and the natural history of non-alcoholic fatty liver disease.J Hepatol2004https://conductscience.org/library/papers/15030972PubMed
1110332677Cause-specific mortality in type 2 diabetes. The Verona Diabetes Study.Diabetes Care1999https://conductscience.org/library/papers/10332677PubMed
1216732016Relations between carotid artery wall thickness and liver histology in subjects with nonalcoholic fatty liver disease.Diabetes Care2006https://conductscience.org/library/papers/16732016PubMed
1314762783Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma.Gastroenterology2004https://conductscience.org/library/papers/14762783PubMed
1415017611Nonalcoholic fatty liver disease in patients with type 2 diabetes.Clin Gastroenterol Hepatol2004https://conductscience.org/library/papers/15017611PubMed
1517133503Accuracy of liver stiffness measurement for the diagnosis of cirrhosis in patients with chronic liver diseases.Hepatology2006https://conductscience.org/library/papers/17133503PubMed
1611826411NASH and insulin resistance: Insulin hypersecretion and specific association with the insulin resistance syndrome.Hepatology2002https://conductscience.org/library/papers/11826411PubMed
1712883486Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C.Hepatology2003https://conductscience.org/library/papers/12883486PubMed
1812029634Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis.Hepatology2002https://conductscience.org/library/papers/12029634PubMed
1916306373Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients.Diabetes2005https://conductscience.org/library/papers/16306373PubMed
2010573511Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.Hepatology1999https://conductscience.org/library/papers/10573511PubMed

See all 51 referencesDownload CSV of references

Cited by20

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 42 citations.

PMIDTitleJournalYearIn PapersSource
35983425Noninvasive, Blood-Based Biomarkers as Screening Tools for Hepatic Fibrosis in People With Type 2 Diabetes.Clin Diabetes2022https://conductscience.org/library/papers/35983425PubMed
34070929Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice?Cancers (Basel)2021https://conductscience.org/library/papers/34070929PubMed
34027112The association between obstructive sleep apnea and non-alcoholic steatohepatitis: a retrospective nationwide inpatient sample analysis.Clin Exp Hepatol2021https://conductscience.org/library/papers/34027112PubMed
33912410Role of diet and lifestyle modification in the management of nonalcoholic fatty liver disease and type 2 diabetes.Tzu Chi Med J2021https://conductscience.org/library/papers/33912410PubMed
31892230Immune Therapy for Liver Cancers.Cancers (Basel)2019https://conductscience.org/library/papers/31892230PubMed
31783782Angiogenesis and immune checkpoint inhibitors as therapies for hepatocellular carcinoma: current knowledge and future research directions.J Immunother Cancer2019https://conductscience.org/library/papers/31783782PubMed
31179513NMR metabolomics identifies over 60 biomarkers associated with Type II Diabetes impairment in db/db mice.Metabolomics2019https://conductscience.org/library/papers/31179513PubMed
30309884Performance of the SteatoTest, ActiTest, NashTest and FibroTest in a multiethnic cohort of patients with type 2 diabetes mellitus.J Investig Med2019https://conductscience.org/library/papers/30309884PubMed
29622904Non-Alcoholic Fatty Liver Disease and Associated Factors among Type 2 Diabetic Patients in Southwest Ethiopia.Ethiop J Health Sci2018https://conductscience.org/library/papers/29622904PubMed
27197688Polyol accumulation in muscle and liver in a mouse model of type 2 diabetes.J Diabetes Complications2016https://conductscience.org/library/papers/27197688PubMed
26985892Extracellular Vesicles: A New Frontier in Biomarker Discovery for Non-Alcoholic Fatty Liver Disease.Int J Mol Sci2016https://conductscience.org/library/papers/26985892PubMed
26861926Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes.Diabetes Care2016https://conductscience.org/library/papers/26861926PubMed
25834320Primary biliary cirrhosis-associated hepatocellular carcinoma in Chinese patients: incidence and risk factors.World J Gastroenterol2015https://conductscience.org/library/papers/25834320PubMed
24991603Evaluating the efficacy of Salsalate on prediabetic and diabetic patients with fatty liver: A randomized clinical trial.J Res Pharm Pract2013https://conductscience.org/library/papers/24991603PubMed
23716995Nonalcoholic fatty liver disease and microvascular complications in type 2 diabetes.World J Gastroenterol2013https://conductscience.org/library/papers/23716995PubMed
23560443Inhibition of Glutaminyl Cyclases alleviates CCL2-mediated inflammation of non-alcoholic fatty liver disease in mice.Int J Exp Pathol2013https://conductscience.org/library/papers/23560443PubMed
23355498Synergism between obesity and alcohol in increasing the risk of hepatocellular carcinoma: a prospective cohort study.Am J Epidemiol2013https://conductscience.org/library/papers/23355498PubMed
23334857Abnormalities in carbohydrate and lipid metabolisms in high-fructose dietfed insulin-resistant rats: amelioration by Catharanthus roseus treatments.J Physiol Biochem2013https://conductscience.org/library/papers/23334857PubMed
23148186An Endocrine Perspective of Nonalcoholic Fatty Liver Disease (NAFLD).Ther Adv Endocrinol Metab2011https://conductscience.org/library/papers/23148186PubMed
22496902Effect of dietary advanced glycation end products on mouse liver.PLoS One2012https://conductscience.org/library/papers/22496902PubMed

Download CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/17547834

GET https://conductscience.org/api/papers/v1/17547834/references?page=2